Background-The results of cohort studies relating sodium (Na) intake to blood pressure-related cardiovascular disease (CVD) are inconsistent. To understand whether methodological issues account for the inconsistency, we reviewed the quality of these studies. Methods and Results-We reviewed cohort studies that examined the association between Na and CVD. We then identified methodological issues with greatest potential to alter the direction of association (reverse causality, systematic error in Na assessment), some potential to alter the direction of association (residual confounding, inadequate follow-up), and the potential to yield false null results (random error in Na assessment, insufficient power). We included 26 studies with 31 independent analyses. Of these, 13 found direct associations between Na and CVD, 8 found inverse associations, 2 found J-shaped associations, and 8 found null associations only. On average there were 3 to 4 methodological issues per study. Issues with greater potential to alter the direction of association were present in all but 1 of the 26 studies (systematic error, 22; reverse causality, 16). Issues with lesser potential to alter the direction of association were present in 18 studies, whereas those with potential to yield false null results were present in 23. Conclusions-Methodological issues may account for the inconsistent findings in currently available observational studies relating Na to CVD. Until well-designed cohort studies in the general population are available, it remains appropriate to base Na guidelines on the robust body of evidence linking Na with elevated blood pressure and the few existing general population trials of the effects of Na reduction on CVD. The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
T he relationship between sodium (Na) intake and blood pressure (BP) is well established, based on a diverse body of evidence including clinical trials. 1 Meta-analyses of randomized controlled trials in both adults and children have found that reducing Na can lead to important reductions in BP. [2] [3] [4] [5] [6] In addition, trials have consistently identified a clear dose-response relationship between Na intake and BP, with progressively lower levels of Na intake being associated with lower levels of BP. [7] [8] [9] Trials that test the efficacy of reduced Na intake on clinical cardiovascular disease (CVD) outcomes in general populations have found that reduction of Na intake is associated with lower CVD, although these trials are few and underpowered. 10 Only 1 published trial, which substituted potassium for ≈50% of dietary Na, was specifically designed to address this question. 11 Six other trials, primarily designed to study the long-term relationship between Na intake and BP, have also reported the effects of Na intake on CVD outcomes, which have subsequently been used in meta-analyses. 10, 12 Although trials designed to address this gap would be ideal, 12, 13 sample size requirements, cost, and the difficulty of sustaining a long-term contrast in Na intake between treatment groups make this challenging. 10, 14 To the best of our knowledge, only 1 trial specifically designed to test the efficacy of Na reduction on CVD outcomes is under way, in China. 15 A 2009 meta-analysis of cohort studies documented a significant direct relationship of Na intake with CVD outcomes 16 ; a more recent meta-analysis that also included trial evidence concluded that lower Na intake is associated with a reduced risk of stroke and fatal coronary heart disease (CHD) in adults, although the quality of the evidence was deemed low. 2 Both found substantial heterogeneity in the results across studies, a component of which resulted from conflicting reports by authors who conducted separate analyses of the same data sets. [17] [18] [19] [20] Hence, it is plausible that some of this heterogeneity results from differences in analytic strategy as well as study design. Since the 2009 meta-analysis, 13 additional studies have been published, with 6 showing either an inverse or J-shaped association between Na intake and CVD.
Letters, editorials, and scientific statements have offered methodological critiques of individual studies, but there has been no systematic assessment of the quality of the available studies.
14,21, 22 The objective of the present report was to assess the quality of cohort studies examining the relationship between Na intake and subsequent CVD and to describe the potential contribution of methodological issues to the heterogeneity of results. To prepare this report, the American Heart Association assembled a group of investigators who were familiar with methodological challenges inherent in the design, conduct, and analysis of prospective studies that relate Na intake to CVD.
Methods
Because many of the methodological challenges pertain to measuring Na intake, we provide a brief overview of the techniques used to estimate Na intake in cohort studies.
Estimating Na Intake
The 2 main approaches are urine collections and dietary surveys. Na intake varies widely from day to day; consequently, although a single day's measurement can be useful in characterizing group intake, it is too imprecise to assess an individual's usual intake. 23 Relying on a single day of data can lead to random errors in Na assessment.
Averaging multiple 24-hour urinary Na collections provides the most accurate characterization of an individual's usual Na intake, because typically >90% of the Na consumed by healthy individuals is recovered in their urine. [23] [24] [25] Collection of even one 24-hour urine specimen, however, carries high participant burden. Therefore, to estimate Na intake, studies typically obtain a single collection of urine (24-hour, overnight, or "spot") rather than multiple collections. Besides the difficulty of assessing usual intake, 24-hour urine collections are often incomplete unless specific approaches are taken to avoid undercollection, 26, 27 with 1 study reporting underestimation in 25% of its samples. 28 Both overnight and spot urine collections are easier for participants and less prone to be incomplete but have been shown to either underestimate (overnight collections) 29 or overestimate (spot urines) 30 24 -hour values. A recent systematic review found that their reliability varied widely. 31 Of particular concern, diurnal variation in Na excretion differs based on medication use 32 and clinical conditions 33, 34 and can adversely impact the validity of these shorter collections as estimates of individual 24-hour Na excretion.
Methods for dietary assessment of Na intake include use of food records, 24-hour recalls, and food frequency questionnaires (FFQs). The ability of food records and 24-hour recalls to capture usual intake depends on how many days are assessed. FFQs aim to capture usual intake by asking about eating habits over months or years, but their accuracy is limited by the number and relevance of food items included, the lack of specific product information, and a high potential for recall bias. 35 In all diet surveys, error in estimating Na intake can arise from (1) inaccurate reporting by participants of the types and quantity of food that they have consumed (Na is highly correlated with calorie intake) 36 ; (2) lack of inclusion of salt added at the table, in condiments, and in some instances during cooking 37 ; and (3) reliance on incomplete and infrequently updated food composition tables to determine the Na content of food. 36 Underreporting of energy intake is particularly problematic in FFQs but is a problem in all dietary surveys. 38 Importantly, underreporting is often influenced by key study variables; for example, overweight and obese study participants commonly underestimate their food intake relative to their leaner counterparts.
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Description and Rationale of Methodological Issues
We identified 3 categories (domains) of methodological issues that apply to observational studies of Na and CVD: (1) Those with the greatest potential to alter the direction of association (in either direction); (2) those with some potential to alter the direction of association but of a lesser magnitude; and (3) those with the potential to lead to a false null result. Table 1 lists the 3 domains and the criteria we applied.
Domain 1: Errors With the Greatest Potential to Alter the Direction of Association
Systematic Error in Na Assessment
Systematic error arises when the measured overall mean Na differs from the true overall mean Na. If the systematic error differs by exposure or disease status, it can have unpredictable effects on estimation of the relationship between Na intake and CVD. 35 As noted above, all types of Na measurement are vulnerable to systematic error in estimating Na intake, although to different extents. Furthermore, the error in both dietary studies and partial urine collections has been shown to differ by clinical characteristics.
We classified studies into 2 groups based on the potential for systematic error inherent in their method of assessment. The first group, lower risk of systematic error, is limited to 24-hour urine collections not collected as part of routine clinical practice that report quality assurance or exclude incomplete collections. The second group, higher risk of systematic error, includes other 24-hour urine collections, all dietary assessment methods, and spot and overnight urine collections. Furthermore, regardless of the type of data collection, the potential for systematic error was determined to be high when participants were instructed to change their Na intake before Na assessment or if we observed systematic error in published results. We identified evidence of systematic error by an implausible difference in mean calories (in diet studies) or urinary creatinine excretion (for urine studies) compared with mean weight (or body mass index) across levels of Na intake.
Potential for Reverse Causality
Reverse causality in Na studies arises when sick individuals included in a study have reduced their Na intake either because of medical advice or an illness-related reduction in food consumption. 21 This may result in a J-shaped relationship leading to the misinterpretation that very low levels of Na intake have resulted in illness, when instead, it is likely that the illness is responsible for the low level of Na intake. 43 Reverse causality is more likely to be a problem in studies with a relatively high percentage of sick participants and when the study outcome is based on mortality rather than incident events. 43 Although it is likely that some level of reverse causality exists in all cohort studies with diet as an exposure, we divided studies into 3 groups to reflect the likelihood that it biased the relationship between Na and CVD. Studies based on general population recruitment that excluded participants with disease at baseline were designated as having the lowest risk of bias; studies using general population recruitment that included participants with disease at baseline were designated • Yes: Study has <80% power to detect a 10% reduction in relative risk for every standard deviation drop in Na intake using a standard calculation (based on the maximum number of CVD events)
• Unlikely: Study has ≥80% power to detect a 10% reduction in relative risk for every standard deviation drop in Na intake BMI indicates body mass index; CHF, congestive heart failure; CVD, cardiovascular disease; ESRD, end-stage renal disease; RCT, randomized controlled trial; SES, socioeconomic status; and Na, sodium. Potential for systematic error in Na assessment:
• High:
-Participants instructed to reduce Na intake or modify diet prior to Na assessment -Na intake measured through food frequency questionnaires, 24-h recalls, food records, spot or overnight urine collections, or 24-h urine collections without evidence of quality control measures -Evidence of systematic error, identified by an implausible difference in mean calories (in diet studies) or urinary creatinine excretion (for urine studies) compared with weight (or BMI) across levels of Na intake.
• Lower:
-24-h urine collections with reported quality control measures Potential for reverse causality:
-Specifically recruited sick participants (pre-existing CVD, diabetes mellitus, CHF, or ESRD) -Removing sick participants from analysis changes direction of association
• Intermediate:
-Sick populations not excluded from general population study -Evidence that despite exclusions, participants with prior CVD were included -Recruitment of populations with existing CVD risk factors (eg, hypertension) -Specifically recruited sick populations but assessed both violations of proportional hazards and excluded early events in sensitivity analysis
• Low: Recruited from the general population and preexisting CVD excluded from analysis Domain 2: Errors with some potential to alter the direction of association in either direction
Potential for residual confounding 1: Incomplete adjustment:
• Yes:
-≥2 of the following major risk factors for CVD: age, sex, race, SES, cholesterol, BMI (or weight), smoking, diabetes mellitus, and (if an RCT) treatment assignment not included in final model -Diet-based studies that do not control for calories in multivariate models -Urine-based studies that do not control for weight, BMI, or creatinine excretion
• Unlikely: Either no apparent errors or minor errors not included above Potential for residual confounding 2: Study imbalance
-Age difference across Na intake groups is >5 y -Sex or race distribution across Na intake groups differs by >20%
• Unlikely: as having an intermediate risk of bias; and studies that specifically recruited sick participants with diseases such as congestive heart failure, end-stage renal disease, or type 1 and type 2 diabetes mellitus were designated as having a high risk of bias. Conducting sensitivity analyses for reverse causality by excluding known sick individuals or events at the beginning of follow-up may not fully account for reverse causality. 43 As such, we considered the potential for bias to be reduced only if the authors performed the above analyses and determined that the proportional hazards assumption was not violated. 44 
Domain 2: Errors With Some Potential to Alter Direction of Association
Potential for Residual Confounding 1: Incomplete Adjustment Bias in linking Na intake and CVD can occur from underadjustment or overadjustment for potential confounding factors. In dietary studies, adjustment for calories may correct for some of the systematic error from inaccurate reporting of food. 35, 45 In urine studies, adjustment for body weight (or body mass index) or creatinine excretion serves the same purpose. Confounding can be reduced by adjustment for major CVD risk factors (body mass index, cholesterol, diabetes mellitus status), demographic characteristics (age, sex, race, and socioeconomic status), and treatment status in observational analyses nested in clinical trials. We classified studies as being incompletely adjusted when these adjustment variables were not included in regression models (Table 1) .
Two variables, potassium and BP, were not included in our criteria for classification. Potassium intake is highly correlated with both Na intake and CVD risk and may modify the relationship between Na intake and CVD. When potassium and Na are measured by the same method (ie, urine collection), the correlation of their errors complicates interpretation of coefficients in linear models. 37, 46 A priori, we had planned to consider studies that adjusted for BP to be overadjusted because BP is likely to be an intermediary variable between Na intake and CVD. However, we dropped it from our criteria because adjustment for BP had no apparent impact on the results in several studies.
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Potential for Residual Confounding 2: Imbalance Across Na Intake Levels
Residual confounding can also be caused by large differences in key confounders (eg, age, sex, race) across exposure categories. In some studies, there are major sociodemographic differences between those reported to consume lower and higher levels of dietary Na that traditional regression methods may not rebalance adequately. We assessed whether the highest and lowest Na intake groups in a study differed by (1) >5 years of age, (2) >20% in the proportion of men and women, or (3) >20% in the proportion of blacks, whites, or other race/ ethnic groups. We classified studies that met ≥1 of the above criteria as being at risk for residual confounding if they did not conduct a stratified analysis on the variable in question.
Inadequate Follow-up
Failure to conduct complete, high-quality follow-up of study participants can also bias results in either direction. 50 We classified studies with >20% loss to follow-up as having the potential for bias because of possible differences in outcomes between those who dropped out and those who remained under observation throughout the period of follow-up.
Domain 3: Errors With the Potential to Lead to a False Null Result
Random Error in Na Assessment
High levels of random error in estimating usual Na intake can limit the ability to assess the relationship between Na intake and disease by biasing results toward the null. 23, 35 Error caused by the high day-to-day variability in Na consumption does not bias the overall mean intake because it can be assumed to be random. 35 We classified studies into 3 groups (high, intermediate, or low) based on their likely level of random error in assessing Na intake. Studies that relied on spot or overnight urines, a single 24-hour dietary recall or urine collection, or a 1-day food record were classified as having a high level of random error. Studies with ≥2 days of food records, 24-hour recalls, or two to four 24-hour urine collections or that used a second measurement on a subset of participants to estimate usual intake were considered to have intermediate levels of random error. Studies with an average of greater than four 24-hour urine measurements were considered to have low potential for random error, as were FFQs. The potential error in an FFQ is more likely systematic than random, because repeating the FFQ will not improve the validity of the assessment.
Insufficient Power
We assessed whether studies were adequately powered to detect a relationship between Na intake and CVD. To simplify the assessment, we applied a standard test: Did the study have 80% power to detect a 10% difference in CVD risk per standard deviation of Na intake? We used Stata 12.1 (StataCorp, College Station, TX) for these calculations, using the study's sample size and the CVD outcome with the largest number of events. When CVD events were not assessed, we substituted all-cause mortality; in these cases, power is likely overstated, because the expected relationship between Na intake and all-cause mortality is less than with CVD. If an article only reported subgroup analyses, we conducted a power calculation for each subgroup.
Literature Review and Data Abstraction
We attempted to identify all observational cohort studies with ≥1 year of follow-up that assessed the relationship between Na intake and CVD. The inclusion criteria were as follows: (1) prospective design, including those nested in clinical trials; (2) use of a dietary method or urine analysis to assess Na intake; and (3) ≥1 of the following outcomes: all-cause mortality, CVD mortality, stroke, CHD, congestive heart failure, or myocardial infarction. To identify eligible studies, we searched both PubMed and Embase. We also reviewed the references of previous systematic reviews. Data were abstracted onto predesigned forms to identify key features of the study.
To ensure consistency in abstracting exposure and outcome data, we used the following guidelines: We abstracted all results that used either absolute Na intake, calorie-adjusted Na intake, or Na-kilocalorie ratio as the exposure estimate. When >1 measure of Na intake was reported, the choice of study results and resultant domain classification was based on our perception of the article's main exposure, typically the one highlighted in the article's abstract. We abstracted results for continuous, categorical, and nonlinear Na intake measures. We reported the results for all outcomes that met our inclusion criteria, with the exception of stroke subtypes. These were only reported where total stroke was unavailable. *Associations listed are from fully adjusted models and use the studies' designated main Na intake variable: Na intake, Na/calories, or calorie-adjusted Na residuals. Listed as significant if either the linear trend was significant or there was a significant difference between the highest and lowest Na intake groups. 0 indicates null; +, positive significance; and −, negative significance. † Presented in strata by sex and combined. ‡ Number in subcohort (case cohort study). §In men only; only crude associations were calculated for women and other outcomes. ‖Showed positive significant results between middle and top of distribution, but overall J shape was not significant. Using the fully adjusted model, we categorized studies according to whether or not they showed a direct, inverse, J-shaped, or null relationship between Na intake and CVD. We reported subgroup-specific results when the overall results were not published (henceforth called substudies). A study or substudy was considered to have a positive association if ≥1 of the exposure-outcome relationships showed a significant positive association and the remainder were null. The same principle was applied to identification of inverse and J-shaped relationships. Each exposure-outcome relationship was not considered an independent finding. A study was considered to show a null relationship only if all of the results were nonsignificant. We considered results to be significant if the P value for the Na intake and CVD relationship was <0.05. J-shaped relationships were assessed only if the authors specifically tested for them (3 studies).
Results
Our literature search identified 3487 publications, of which 81 met ≥1 of the inclusion criteria. A total of 26 articles met all of our criteria for inclusion in the present analysis, 17-20,47-49,52-70 but 1 duplicate publication was excluded. 70 One additional report was identified from a prior systematic review, 16 ,71 which resulted in 26 articles.
The 26 included articles reported results for a total of 31 independent analyses conducted in 285 530 participants. Three articles used data from the National Health and Nutrition Examination Survey (NHANES) I, 17,18,52 and 2 used NHANES III data. 19, 20 Participants were from East Asia, North America, Europe, and Australia. Sixteen articles were based on general population recruitment and 10 on recruitment of participants at elevated risk of CVD (Table 2) . Individual studies assessed the relationship between Na and 1 to 6 clinical CVD outcomes. Nine studies assessed the relationship with stroke incidence and 4 with stroke mortality; 9 assessed CHD or myocardial infarction incidence, and 6 assessed CHD mortality; 5 assessed any CVD incidence, and 13 assessed any CVD mortality; 1 assessed congestive heart failure incidence, and 4 assessed congestive heart failure-related hospitalization or mortality; and 15 assessed all-cause mortality. Definitions of CVD were inconsistent across studies.
Within the 31 independent analyses, results varied across clinical outcomes, but no study or substudy reported a positive significant finding for 1 outcome and an inverse or J-shaped significant finding for another. Although null findings were the most common (reported for ≥1 outcome in more than half the studies surveyed), only 8 studies or substudies reported solely null associations. Overall, there was a significant, positive association between Na and ≥1 outcome in 13 of the studies or substudies, at least 1 significant inverse association in 8 and J-shaped associations in 2. Findings for stroke (7 null, 3 positive), stroke mortality (3 null, 3 positive), and CHD mortality (6 null, 2 positive) were the most consistent, with no inverse associations. Findings for CHD incidence (8 null, 2 positive, 1 inverse), CVD incidence (2 null, 2 positive, 1 inverse), CVD mortality (5 null, 3 positive, 6 inverse), and all-cause mortality (8 null, 5 positive, 4 inverse) were more mixed (Table 2; online-only Data Supplement Table 1 ).
Domain 1: Errors With the Greatest Potential to Alter the Direction of Association
Systematic Error in Na Assessment Na intake was assessed by means of urine collections in 11 studies, 9 of which used at least one 24-hour urine collection. In the remaining 15 studies, dietary methods were used to assess Na intake, with 10 using 24-hour recalls or food records and 5 using FFQs. Of the 9 studies that used 24-hour urine collection, 6 reported some quality assurance procedures or excluded incomplete collection. Of these 5, 1 measured Na after participants were asked to reduce their Na intake 69 and 1 provided data documenting systematic error, 47 and thus, only 4 were classified as having a lower risk of systematic error. One of the studies that used food records also asked participants to alter their diet to facilitate measurement of Na intake. 65 Although most studies did not provide the level of information required to assess whether systematic error was present, we identified evidence of it in 1 study that used 24-hour urine collections and in 5 that used dietary surveys. One study showed evidence of undercollection of 24-hour urine samples: In men, creatinine excretion levels differed by 24.8% between the lowest and highest tertiles of Na intake, whereas weight differed by just 9.8% in these tertiles 47 ( Figure; online-only Data Supplement Table 2a ). The Figure also provides an example typical of the 5 dietary studies with observed systematic error: Calorie intake differed by 49.8% between men in the lowest and highest quartile of Na intake, whereas the corresponding difference in weight was only 2.2%
18 (online-only Data Supplement Table 2b ).
Potential for Reverse Causality
Seven studies that recruited participants with congestive heart failure, end-stage renal disease, type 1 and type 2 diabetes mellitus, or prior CVD were classified as having a high potential for reverse causality. Another 7 studies did not exclude sick participants and thus were classified as having an intermediate level of risk (number of included participants with known prior CVD ranged from 2%-21%). Two additional studies were assessed as having intermediate risk: 1 excluded sick participants at baseline, but 18% still had evidence of previous cardiac disease 63 ; another recruited sick participants but met our criteria for testing for reverse causation. 49 The remaining 10 studies were judged to have a low potential for reverse causality, recruiting general samples and excluding participants with known prior CVD (Table 3 ; online-only Data Supplement Table 3 ).
Domain 2: Errors With Some Potential to Alter the Direction of Association
Potential for Residual Confounding 1: Incomplete Adjustment More than half (14) of the studies had a potential risk of bias because of underadjustment. Of these, 2 controlled for age and sex only; 7 used a urinary assessment of Na intake but did not control for creatinine excretion or weight (or body mass index); and an additional 5 did not control for ≥2 traditional CVD risk factors or demographic variables (Table 3; online-only Data Supplement Table 4a ). March 11, 2014
Potential for Residual Confounding 2: Imbalance Across Groups
Eight studies were deemed to lack balance across categories of Na intake. Two studies had a >5-year age difference between the highest and lowest Na intake groups, 4 had a >20 percentage point difference in the percentage of men across Na intake groups, and another 3 met both criteria. In 4 of the studies identified above, analyses stratified by the relevant confounder indicated a low risk of residual confounding. The potential for residual confounding was deemed low in 9 studies and could not be assessed in another 9 studies because of lack of information (Table 3; online-only Data Supplement Table 4b ).
Inadequate Follow-up
Two studies had a >20% loss to follow-up (for nonfatal outcomes), and 4 studies did not report the completeness of follow-up (Table 3 ; online-only Data Supplement Table 5 ). Follow-up quality was generally high, with most studies reporting that cases were confirmed with medical records; however, 9 studies relied solely on data from death registries to classify the cause of death.
Domain 3: Errors With the Potential to Lead to a False Null Result
Random Error in Na Assessment
Assessment of random error depended on both the type and frequency of Na measurements. Of the 11 studies that used urine collections to assess Na intake, only 2 used multiple urine collections, thus reducing the likelihood of random error: Ekinci et al 64 used one to five 24-hour collections, and Cook et al used 3 to 7 collections. 66 Of the 10 studies that used 24-hour recall or food records to assess Na intake, 4 assessed >1 day of intake (including 1 that used a second day of intake from a subset of participants to estimate usual intake) 20 and had an intermediate likelihood of random error. Five studies used FFQs to assess Na intake and were designated as having low potential for random error (Table 3; online-only Data  Supplement Tables 2a and 2b ).
Insufficient Power
Among the 30 studies or sub-studies in which statistical power could be assessed, 8 met our threshold of 80% power to detect a 10% difference in CVD risk. Power was <50% in 15 substudies (Table 3 ; online-only Data Supplement Table 5 ).
Methodological Challenges by Direction of Association
On average, we identified 3 to 4 methodological challenges in each of the 31 studies or substudies. Methodological challenges were evident no matter the direction of the association between Na and CVD. Those in domain 1 (errors with the greatest potential to alter the direction of association) were approximately evenly distributed regardless of the direction of the association, although they were slightly more common in studies with an inverse and J-shaped association than in studies with a positive association (7/10 versus 7/13; potential for systematic error 9/10 versus 10/13). Domain 2 (errors with lower potential to alter the direction of association) followed a similar pattern (7/10 versus 7/13 for inadequate adjustment; 5/10 versus 4/6 for imbalance across groups; 1/9 versus 0/12 for inadequate follow-up). Errors in domain 3 (those likely to lead to a false null result) were the most common overall and were found in all but 3 studies (Table 3) . Of the null studies, 63% (5/8) had high levels of random error, and 71% (5/7) had <80% power.
Discussion
The present study has 2 main findings. First, methodological challenges were common across all of the assessed domains. Errors with a potential to alter the direction of the association in either direction (domains 1 and 2) were common across all studies and slightly more prevalent in studies that reported an inverse or J-shaped relationship. Errors likely to lead to a false null result (domain 3) were also common, perhaps accounting for the preponderance of null outcomes. Second, many of the reports provided insufficient information to assess study quality. This was particularly true for assessment of systematic errors in Na intake.
The potential for systematic error in Na assessment is a major concern. One way to partially reduce the systematic error from underreporting of foods in dietary studies is to correct for energy intake; however, this technique does not eliminate error attributable to inaccurate food composition tables or failure to include discretionary salt use in the assessment. It also means assessing Na indexed to calories rather than absolute Na levels, the approach used in the current dietary recommendations for Na of 1500 or 2300 mg of Na per day regardless of calorie intake. 72 Standardizing to creatinine excretion in 24-hour urine collections can also reduce systematic error that arises through undercollection, although this was rarely done in the studies we assessed.
The use of more than one 24-hour urine collection should remain the "gold standard" for measurement of individual level Na intake in general population studies. Nonetheless, 24-hour urinary Na measurements are prone to underestimate Na intake because of incomplete collection unless specific measures are taken to prevent this problem. 26, 27 Although we gave studies credit for any quality assurance measure, to obtain an unbiased and complete assessment, investigators need to 26 Most of the included articles used urine samples that had either been collected in studies in which assessment of Na relationships was not the primary goal or as part of routine clinical practice. When quality assurance information related to urine collection was provided, it was often quite limited. Only 5 of the 9 included studies reported quality assurance procedures or excluded participants on the basis of incomplete collections, 47, 54, 57, 60, 66 and 1 excluded incomplete collections in a sensitivity analysis. 69 Exclusions in these studies ranged from <1% to 11% compared with the 20% to 25% reported in studies that used PABA (p-aminobenzoic acid) testing 28 (onlineonly Data Supplement Table 2a ).
Of the 26 articles, 12 were published after 2010. These recent articles more often recruited sick study participants (8/12) . It is important to understand the relationship between Na intake and CVD in sick patients because it may differ from the relationship in the general population; however, such findings are not directly relevant to recommendations for the general population. Differences in findings between general population cohorts and studies with a high prevalence of sick patients may also be related to reverse causality in the latter group. This is a particularly relevant concern in studies of mortality outcomes, 43 which are frequently of interest in investigations conducted in sick patients. In addition, valid estimation of 24-hour urinary Na can be challenging in this setting. 73 The impact of methodological choices on study findings is demonstrated by the striking differences in results from separate analyses of the same study in which investigators used different inclusion criteria and analytic approaches. He et al 17 reported a positive significant association between Na intake and all-cause mortality in overweight NHANES I participants and a null association in normal-weight participants. In contrast, Alderman et al 18 reported a significant inverse association between absolute levels of Na intake and all-cause mortality in all participants. In addition to the use of subgroup analyses in the study by He et al, 17 differences included the following: (1) Alderman et al 18 did not exclude participants with CVD or those on a low-salt diet to reduce their blood pressure (≈13%); and (2) Alderman et al 18 used models that did not control for key CVD risk factors but included the Na-kilocalorie ratio, Na intake, and kilocalories simultaneously in the model. In an analysis of NHANES III, Cohen et al 19 found a significant inverse relationship linking Na intake to CVD mortality (null for all-cause mortality). In contrast, an exploration of the same data set by Yang et al 20 identified a significant positive relationship between Na intake and all-cause mortality (null for CVD mortality). The main differences between the 2 studies were that Yang et al 20 used longer follow-up and used estimated usual Na intake rather than a single dietary recall. When Yang et al 20 used a single dietary recall, the results for all-cause mortality were null and thus similar to those reported by Cohen et al 19 (online-only Data Supplement Table 6 ). The present review has several strengths. Although meta-analyses of observational studies linking Na intake and clinical cardiovascular outcomes have been conducted, this is the first systematic review focusing specifically on the quality of these studies. We identified 3 principal domains that encompass the potential for systematic and random error. For each domain, we defined objective standards and applied them consistently to all studies. Generic quality metrics (eg, GRADE [Grading of Recommendations Assessment, Development and Evaluation] 74 or the Downs and Black checklist 75 ) lack specific guidance on how to assess bias, particularly as it relates to nutrition-specific issues. Furthermore, some automatically downgrade observational studies regardless of their quality. Finally, studies with a single major flaw that leads to systematic bias may nonetheless receive an overall high score based on other criteria.
The present review also has limitations. As with any classification system, the results are not purely quantitative and required judgments by the study team. However, to the extent possible, we applied uniform standards to the identification of potential errors in each study. In some cases, a customized study-specific approach to managing and avoiding error may be more appropriate. For instance, it may be prudent to control for different variables in studies of dialysis patients compared with the general population. Second, in many of the reports, there was insufficient information to assess the potential for methodological flaws, particularly in terms of assessing the presence of systematic errors in Na measurement. Finally, we did not assess the effect on type 1 error given the large number of outcomes, subgroups, and analytic approaches in many studies.
The present analysis can serve as a resource for investigators during the design, conduct, and analysis of future studies. Studies in general population samples, that is, broadly inclusive studies that are not restricted to individuals with a specific disease or condition, have the potential to provide the most valuable information, both because of their larger policy implications and their enhanced potential to avoid reverse causality. Furthermore, studies should focus on CVD incidence, if possible, because this outcome is less prone to be influenced by reverse causality. Another important lesson from the existing reports is that Na measurement needs more careful attention during study design and conduct, not simply during the analysis. Collection of multiple complete 24-hour urine specimens is a substantial burden for study participants, but there is, as yet, no satisfactory substitute. Additional research on the validity of overnight, spot, and timed urine collections may be useful, but diurnal variation in Na excretion makes it unlikely that they can serve as a satisfactory substitute for 24-hour collections at the individual level. Finally, the present study highlights the need for more complete reporting by authors so that reviewers and readers can assess the completeness of urine collections and evaluate other potential sources of error. Body weight (or body mass index) and urine creatinine excretion should be reported by categories of Na intake in studies that use 24-hour urine collections to assess Na intake, whereas total calorie intake should be reported in studies that use a dietary collection method.
The present study can also help researchers and policy makers interpret the results of existing and future studies of the relationship between Na intake and CVD. Methodological issues have the potential to qualitatively affect the results and interpretation of studies. The present study has shown that flaws are common in the studies that have been conducted to date, especially those conducted in sick individuals. However, not all studies are flawed to the same extent. Studies with the lowest risk of reverse causality and systematic error in exposure assessment are likely to be the least biased. In general, we recommend reliance on studies conducted in the general population that used 24-hour urine collections with available quality assurance. Although recent meta-analyses of this body of literature have been useful in summarizing the relationship between Na and CVD outcomes, novel methods that allow for classification of studies and then weighting of them by likely level of bias could improve the validity of results.
Overall, however, we do not recommend using this body of literature to set specific cut points for Na intake recommendations, as a few recent reports have done. Using the literature reviewed in the present report plus a few relevant trials, the Institute of Medicine found that the evidence for the current US Dietary Guidelines 2300 mg/d recommendation was compelling but that data for limiting intake to 1500 mg/d in subgroups were insufficient. 76 A recent article by O'Donnell et al, 77 also using the same body of literature, suggested an even higher threshold for healthy Na intake. However, both correctly point out that given the multiplicity of different measures of intake and the lack of standardization, it is difficult to make comparisons across studies to determine an optimal level of intake. For the foreseeable future, the high-quality body of evidence linking Na intake to BP 2 should remain the basis for setting recommended levels of Na intake.
In conclusion, it is difficult to conduct rigorous, high-quality investigations of the relationship between Na intake and CVD. Most of the available information on this topic has been derived from secondary analyses of studies that were not designed to answer this question. There is a high likelihood that similar additional reports will be published and may suffer from the same biases and methodological flaws highlighted here. We hope that the present report will provide a blueprint to gauge the quality of these studies and to ensure that Na policies are based on the best data available.
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